Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Serum is an ideal biological sample that contains an archive of information due to the presence of a variety of proteins released by diseased tissue, and serum proteomics has gained considerable interest for the disease biomarker discovery. Easy accessibility and rapid protein changes in response to disease pathogenesis makes serum an attractive sample for clinical research. Despite these advantages, the analysis of serum proteome is very challenging due to the wide dynamic range of proteins, difficulty in finding low‐abundance target analytes due to the presence of high‐abundance serum proteins, high levels of salts and other interfering compounds, variations among individuals and paucity of reproducibility. Sample preparation introduces pre‐analytical variations and poses major challenges to analyze the serum proteome. The label‐free detection techniques such as surface plasmon resonance, microcantilever, few nanotechniques and different resonators are rapidly emerging for the analysis of serum proteome and they have exhibited potential to overcome few limitations of the conventional techniques. In this article, we will discuss the current status of serum proteome analysis for the biomarker discovery and address key technological advancements, with a focus on challenges and amenable solutions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955 · cited 1×
“Detection of low-abundance serum protein biomarkers that requires comprehensive coverage of the proteome is difficult for MS analysis, unless coupled to various fractionation methods [81].”
MethodQuantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins
Anderson, L., & Hunter, C. L. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500331-mcp200 · Cited by 1,230
Cited by
You, Y., Bai, C., Wang, W., Zhan, T., Hu, X., Hao, F., Xia, M., Liu, Y., Ma, T., Liu, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40003-0 · Cited by 1
Metadata
- Authors
- Ray, S., Reddy, P. J., Jain, R., Gollapalli, K., Moiyadi, A., & Srivastava, S.
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2011-05-04
- Volume
- 11
- Issue
- 11
- Pages
- 2139-2161
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W2153446989
- Cited by
- 224
- References
- 6
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead. https://app.cochat.ai/papers/10.1002/pmic.201000460
- The paper
- Ray, S., Reddy, P. J., Jain, R., Gollapalli, K., Moiyadi, A., & Srivastava, S. (2011). Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead. PROTEOMICS. https://doi.org/10.1002/pmic.201000460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.